Stephen I Rennard

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1393531/publications.pdf

Version: 2024-02-01

302 papers	24,973 citations	7568 77 h-index	8167 148 g-index
378 all docs	378 docs citations	378 times ranked	19170 citing authors

#	Article	IF	Citations
1	Waiting for Actionable Evidence: Roflumilast or Azithromycin?. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2022, 9, 1-3.	0.7	2
2	Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2022, 9, 111-121.	0.7	6
3	Response. Chest, 2022, 161, e249-e250.	0.8	0
4	Wireless, Battery Free Wearable Electronic Nose. , 2022, , .		1
5	Objectively Measured Physical Activity in Patients with COPD: Recommendations from an International Task Force on Physical Activity. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 528-550.	0.7	24
6	Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images. Scientific Reports, 2021, 11, 4916.	3.3	12
7	Relationship between Emphysema Progression at CT and Mortality in Ever-Smokers: Results from the COPDGene and ECLIPSE Cohorts. Radiology, 2021, 299, 222-231.	7.3	27
8	Small airway determinants of airflow limitation in chronic obstructive pulmonary disease. Thorax, 2021, 76, 1079-1088.	5.6	17
9	Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). International Journal of COPD, 2021, Volume 16, 1477-1496.	2.3	8
10	Postdeployment Respiratory Syndrome in Soldiers With Chronic Exertional Dyspnea. American Journal of Surgical Pathology, 2021, 45, 1587-1596.	3.7	16
11	Objectively Measured Physical Activity as a COPD Clinical Trial Outcome. Chest, 2021, 160, 2080-2100.	0.8	17
12	Seven Pillars of Small Airways Disease in Asthma and COPD. Chest, 2021, 160, 114-134.	0.8	22
13	Genetic variation in genes regulating skeletal muscle regeneration and tissue remodelling associated with weight loss in chronic obstructive pulmonary disease. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1803-1817.	7.3	11
14	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. European Respiratory Journal, 2021, 57, 2001339.	6.7	26
15	Machine Learning Characterization of COPD Subtypes. Chest, 2020, 157, 1147-1157.	0.8	44
16	Agonist-specific desensitization of PGE2-stimulated cAMP signaling due to upregulated phosphodiesterase expression in human lung fibroblasts. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 843-856.	3.0	11
17	Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD subjects. Scientific Reports, 2020, 10, 20133.	3.3	8
18	Electronic cigarette extract induced toxic effect in iPS-derived cardiomyocytes. BMC Cardiovascular Disorders, 2020, 20, 357.	1.7	8

#	Article	IF	Citations
19	Response. Chest, 2020, 158, 2232.	0.8	0
20	Co-Morbidity Patterns Identified Using Latent Class Analysis of Medications Predict All-Cause Mortality Independent of Other Known Risk Factors: The COPDGene^{Â®} Study . Clinical Epidemiology, 2020, Volume 12, 1171-1181.	3.0	6
21	Heme metabolism genes Downregulated in COPD Cachexia. Respiratory Research, 2020, 21, 100.	3.6	4
22	Smaller Left Ventricle Size at Noncontrast CT Is Associated with Lower Mortality in COPDGene Participants. Radiology, 2020, 296, 208-215.	7.3	6
23	Chicken Soup in the Time of COVID. Chest, 2020, 158, 864-865.	0.8	12
24	Outcomes consequent to â€œearlyâ€•COPD for interventional studies. European Respiratory Journal, 2020, 55, 1902380.	6.7	0
25	Improving the evaluation of COPD exacerbation treatment effects by accounting for early treatment discontinuations: a post-hoc analysis of randomized clinical trials. Respiratory Research, 2020, 21, 158.	3.6	3
26	COPD Patients Have a Restricted Breathing Pattern That Persists with Increased Metabolic Demands. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 245-252.	1.6	6
27	COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development. Respiratory Medicine, 2020, 173, 106175.	2.9	4
28	Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS). Respiratory Research, 2019, 20, 153.	3.6	25
29	Bronchoalveolar Lavage Fluid from COPD Patients Reveals More Compounds Associated with Disease than Matched Plasma. Metabolites, 2019, 9, 157.	2.9	32
30	TGF-Î² induces a heart failure phenotype via fibroblasts exosome signaling. Heliyon, 2019, 5, e02633.	3.2	15
31	Itâ€™s more than low BMI: prevalence of cachexia and associated mortality in COPD. Respiratory Research, 2019, 20, 100.	3.6	66
32	Turning subtypes into disease axes to improve prediction of COPD progression. Thorax, 2019, 74, 906-909.	5.6	3
33	Diagnosis and management of asthma, COPD and asthmaâ€COPD overlap among primary care physicians and respiratory/allergy specialists: A global survey. Clinical Respiratory Journal, 2019, 13, 355-367.	1.6	11
34	Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. Nature Genetics, 2019, 51, 494-505.	21.4	257
35	Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy. Annals of the American Thoracic Society, 2019, 16, 439-446.	3.2	18
36	Introducing the New COPD Pocket Consultant Guide App: Can A Digital Approach Improve Care? A Statement of the COPD Foundation. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 210-220.	0.7	3

#	Article	IF	Citations
37	Human airway branch variation and chronic obstructive pulmonary disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E974-E981.	7.1	80
38	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1540-1551.	5.6	185
39	Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. Thorax, 2018, 73, 414-421.	5.6	96
40	Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respiratory Medicine,the, 2018, 6, 117-126.	10.7	298
41	Deterioration of Limb Muscle Function during Acute Exacerbation of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 433-449.	5.6	64
42	Alveolar eosinophilia in current smokers with chronic obstructive pulmonary disease in the SPIROMICS cohort. Journal of Allergy and Clinical Immunology, 2018, 141, 429-432.	2.9	12
43	Simultaneous LCâ€“MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF. Biomedical Chromatography, 2018, 32, e4102.	1.7	26
44	Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). Respiratory Research, 2018, 19, 178.	3.6	20
45	Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD. International Journal of COPD, 2018, Volume 13, 813-822.	2.3	21
46	Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1268-1278.	5.6	60
47	Whole exome sequencing analysis in severe chronic obstructive pulmonary disease. Human Molecular Genetics, 2018, 27, 3801-3812.	2.9	32
48	The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. International Journal of COPD, 2018, Volume 13, 1009-1019.	2.3	42
49	Can CAPTURE be used to identify undiagnosed patients with mild-to-moderate COPD likely to benefit from treatment?. International Journal of COPD, 2018, Volume 13, 1901-1912.	2.3	12
50	Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. Nature Genetics, 2017, 49, 426-432.	21.4	306
51	Integrative Genomics of Emphysema-Associated Genes Reveals Potential Disease Biomarkers. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 411-418.	2.9	28
52	Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. Annals of the American Thoracic Society, 2017, 14, 636-642.	3.2	30
53	Network-based analysis reveals novel gene signatures in peripheral blood of patients with chronic obstructive pulmonary disease. Respiratory Research, 2017, 18, 72.	3.6	31
54	Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. Chest, 2017, 151, 340-357.	0.8	91

#	Article	IF	Citations
55	Do COPD subtypes really exist? COPD heterogeneity and clustering in 10 independent cohorts. Thorax, 2017, 72, 998-1006.	5.6	65
56	A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine, 2017, 125, 39-48.	2.9	28
57	Patients with Chronic Obstructive Pulmonary Disease Walk with Altered Step Time and Step Width Variability as Compared with Healthy Control Subjects. Annals of the American Thoracic Society, 2017, 14, 858-866.	3.2	32
58	Body mass index change in gastrointestinal cancer and chronic obstructive pulmonary disease is associated with Dedicator of Cytokinesis 1. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 428-436.	7.3	13
59	Chest computed tomography-derived lowÂfat-free mass index and mortality inÂCOPD. European Respiratory Journal, 2017, 50, 1701134.	6.7	53
60	Gait deficiencies associated with peripheral artery disease are different than chronic obstructive pulmonary disease. Gait and Posture, 2017, 57, 258-264.	1.4	10
61	Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine,the, 2017, 5, 619-626.	10.7	219
62	A New Approach for Identifying Patients with Undiagnosed Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 748-756.	5.6	100
63	Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 473-481.	5.6	101
64	The St. Georgeâ€™s Respiratory Questionnaire Appendix to the Food and Drug Administration Draft Guidance on COPD. Chest, 2017, 152, 914-916.	0.8	1
65	The COPD Biomarkers Qualification Consortium Database: Baseline Characteristics of the St Georgeâ€™s Respiratory Questionnaire Dataset. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 108-119.	0.7	10
66	Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease. PLoS ONE, 2017, 12, e0184039.	2.5	16
67	Variability in objective and subjective measures affects baseline values in studies of patients with COPD. PLoS ONE, 2017, 12, e0184606.	2.5	20
68	The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 177-185.	0.7	22
69	St Georgeâ€™s Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient Data in the COPD Biomarkers Qualification Consortium Database. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 137-145.	0.7	20
70	Socioeconomic Status as a Determinant of Health Status Treatment Response in COPD Trials. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 146-154.	0.7	10
71	Baseline Severity as Predictor of Change in St Georgeâ€™s Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients. Chronic Obstructive Pulmonary Diseases (Miami,) Tj ETQq1 1 0.784314 rgBT /Overlo		
72	Whatâ€™s New with the St Georgeâ€™s Respiratory Questionnaire and Why Do We Care?. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 79-82.	0.7	4

#	Article	IF	Citations
73	Responder Analyses for Treatment Effects in COPD Using the St Georgeâ€™s Respiratory Questionnaire. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 120-127.	0.7	8
74	Interpreting patient-reported outcomes from clinical trials in COPD: a discussion. International Journal of COPD, 2016, Volume 11, 3069-3078.	2.3	21
75	Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β₂-agonist fixed-dose combination: RE²SPOND rationale and study design. International Journal of COPD, 2016, Volume 11, 1921-1928.	2.3	9
76	Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2016, 13, 1016-1025.	3.2	36
77	Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis. Respiratory Research, 2016, 17, 103.	3.6	24
78	Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort. Thorax, 2016, 71, 411-420.	5.6	14
79	Age-Related Differences in Health-Related Quality of Life in COPD. Chest, 2016, 149, 927-935.	0.8	41
80	The Effect of Different Case Definitions of Current Smoking on the Discovery of Smoking-Related Blood Gene Expression Signatures in Chronic Obstructive Pulmonary Disease. Nicotine and Tobacco Research, 2016, 18, 1903-1909.	2.6	18
81	Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive PulmonaryÂDisease. Journal of the American Medical Directors Association, 2016, 17, 712-718.	2.5	77
82	Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. Respiratory Medicine, 2016, 119, 87-95.	2.9	29
83	Effect of tiotropium on night-time awakening and daily rescue medication use in patients with COPD. Respiratory Research, 2016, 17, 27.	3.6	8
84	The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1483-1493.	5.6	83
85	The Relationship between Dietary Fiber Intake and Lung Function in the National Health and Nutrition Examination Surveys. Annals of the American Thoracic Society, 2016, 13, 643-650.	3.2	49
86	Exome Array Analysis Identifies a Common Variant in IL27 Associated with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 48-57.	5.6	52
87	Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 607-613.	5.6	104
88	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. PLoS Genetics, 2016, 12, e1006011.	3.5	88
89	COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry. PLoS ONE, 2016, 11, e0161129.	2.5	19
90	MicroRNAs as Therapeutic Targets in Lung Disease: Prospects and Challenges. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2016, 3, 382-388.	0.7	16

#	Article	IF	Citations
91	Rationale for a Redundant Formulary. The Hawthorne Effect and the Art of Medicine. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1224-1225.	5.6	3
92	The Effect of Statins on Blood Gene Expression in COPD. PLoS ONE, 2015, 10, e0140022.	2.5	16
93	Effect of Varenicline on Smoking Cessation Through Smoking Reduction. JAMA - Journal of the American Medical Association, 2015, 313, 687.	7.4	173
94	CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1001-1011.	5.6	197
95	Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis. Annals of the American Thoracic Society, 2015, 12, 303-312.	3.2	126
96	Design of a multi-center immunophenotyping analysis of peripheral blood, sputum and bronchoalveolar lavage fluid in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). Journal of Translational Medicine, 2015, 13, 19.	4.4	41
97	Identifying a gene expression signature of frequent COPD exacerbations in peripheral blood using network methods. BMC Medical Genomics, 2015, 8, 1.	1.5	78
98	Efficacy of an inhaled corticosteroid/long-acting Î²2-agonist combination in symptomatic COPD patients in GOLD groups B and D. European Respiratory Journal, 2015, 46, 255-258.	6.7	0
99	Clinical and prognostic heterogeneity of C and D GOLD groups. European Respiratory Journal, 2015, 46, 250-254.	6.7	11
100	Early chronic obstructive pulmonary disease: definition, assessment, and prevention. Lancet, The, 2015, 385, 1778-1788.	13.7	176
101	Effect of culture conditions on microRNA expression in primary adult control and COPD lung fibroblasts in vitro. In Vitro Cellular and Developmental Biology - Animal, 2015, 51, 390-399.	1.5	16
102	Gait mechanics in patients with chronic obstructive pulmonary disease. Respiratory Research, 2015, 16, 31.	3.6	21
103	One-year change in health status and subsequent outcomes in COPD. Thorax, 2015, 70, 420-425.	5.6	50
104	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, e4-e27.	5.6	166
105	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Journal, 2015, 45, 879-905.	6.7	138
106	The Promise of Observational Studies (ECLIPSE, SPIROMICS, and COPDGene) in Achieving the Goal of Personalized Treatment of Chronic Obstructive Pulmonary Disease. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 478-490.	2.1	15
107	Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respiratory Medicine, 2015, 109, 1138-1146.	2.9	77
108	Continuous fat-free mass decline in COPD: fact or fiction?. European Respiratory Journal, 2015, 46, 1496-1498.	6.7	12

#	Article	IF	Citations
109	Prostaglandin E2 switches from a stimulator to an inhibitor of cell migration after epithelial-to-mesenchymal transition. Prostaglandins and Other Lipid Mediators, 2015, 116-117, 1-9.	1.9	16
110	Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci. Human Molecular Genetics, 2015, 24, 1200-1210.	2.9	43
111	COPD9USA June 2015. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2015, 2, 343-366.	0.7	1
112	Inhibition of Microâ€RNA 146a Expression in Lung Fibroblasts by Fluticasone Propionate, Salmeterol Xinafoate, and Related Agents. FASEB Journal, 2015, 29, 619.12.	0.5	0
113	Vitamin D Modulates Prostaglandin E₂ Synthesis and Degradation in Human Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 40-50.	2.9	65
114	A Simplified Score to Quantify Comorbidity in COPD. PLoS ONE, 2014, 9, e114438.	2.5	58
115	Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 2, 23-34.	0.7	76
116	Influence of diet and obesity on COPD development and outcomes. International Journal of COPD, 2014, 9, 723.	2.3	90
117	Chronic Obstructive Pulmonary Disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Annals of the American Thoracic Society, 2014, 11, S154-S160.	3.2	21
118	Sexually-dimorphic targeting of functionally-related genes in COPD. BMC Systems Biology, 2014, 8, 118.	3.0	47
119	Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respiratory Research, 2014, 15, 123.	3.6	130
120	Reprogramming of COPD lung fibroblasts through formation of induced pluripotent stem cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 306, L552-L565.	2.9	13
121	Fibroblasts that resist cigarette smoke-induced senescence acquire profibrotic phenotypes. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 307, L364-L373.	2.9	34
122	Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS): TableÂ1. Thorax, 2014, 69, 492-495.	5.6	277
123	Location, location, location: studying anatomically comparable airways is highly relevant to understanding COPD. Thorax, 2014, 69, 1049-1050.	5.6	3
124	Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials. International Journal of COPD, 2014, 9, 657.	2.3	11
125	Comparison of spatially matched airways reveals thinner airway walls in COPD. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study and the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax, 2014, 69, 987-996.	5.6	114
126	Radiological correlates and clinical implications of the paradoxical lung function response to Î²2 agonists: an observational study. Lancet Respiratory Medicine,the, 2014, 2, 911-918.	10.7	21

#	Article	IF	Citations
127	Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. Respiratory Medicine, 2014, 108, 1647-1654.	2.9	22
128	Chest CT Measures of Muscle and Adipose Tissue in COPD. Academic Radiology, 2014, 21, 1255-1261.	2.5	50
129	Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 2014, 14, 118.	2.0	23
130	Smoking Cessation. Clinics in Chest Medicine, 2014, 35, 165-176.	2.1	22
131	Quantitative Computed Tomography Measures of Pectoralis Muscle Area and Disease Severity in Chronic Obstructive Pulmonary Disease. A Cross-Sectional Study. Annals of the American Thoracic Society, 2014, 11, 326-334.	3.2	168
132	Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD. Drugs, 2014, 74, 1635-1657.	10.9	14
133	Matrix metalloproteinase-9 activates TGF-Î² and stimulates fibroblast contraction of collagen gels. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 306, L1006-L1015.	2.9	156
134	Lessons from ECLIPSE: a review of COPD biomarkers. Thorax, 2014, 69, 666-672.	5.6	125
135	Should We View Chronic Obstructive Pulmonary Disease Differently after ECLIPSE?. A Clinical Perspective from the Study Team. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1022-1030.	5.6	130
136	The Association Between Dietary Intake and Phenotypical Characteristics of COPD in the ECLIPSE Cohort. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 1, 115-124.	0.7	9
137	The COPD Foundation Pocket Consultant Guide. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 1, 83-87.	0.7	3
138	Cytotoxicity and gene expression changes induced by inorganic and organic trivalent arsenicals in human cells. Toxicology, 2013, 312, 18-29.	4.2	42
139	Systemic Soluble Receptor for Advanced Glycation Endproducts Is a Biomarker of Emphysema and Associated with AGER Genetic Variants in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 948-957.	5.6	138
140	ACCORD COPD II: A Randomized Clinical Trial to Evaluate the 12-Week Efficacy and Safety of Twice-Daily Aclidinium Bromide in Chronic Obstructive Pulmonary Disease Patients. Clinical Drug Investigation, 2013, 33, 893-904.	2.2	39
141	The COPD Biomarker Qualification Consortium (CBQC). COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 367-377.	1.6	67
142	Introducing the COPD Foundation Guide for Diagnosis and Management of COPD, Recommendations of the COPD Foundation. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 378-389.	1.6	45
143	Long-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Respiratory Medicine, 2013, 107, 424-432.	2.9	20
144	Smad3 mediates cigarette smoke extract (CSE) induction of VEGF release by human fetal lung fibroblasts. Toxicology Letters, 2013, 220, 126-134.	0.8	22

#	Article	IF	Citations
145	The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respiratory Medicine,the, 2013, 1, 129-136.	10.7	224
146	Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 382-386.	5.6	257
147	Phosphodiesterase-4 Inhibition Augments Human Lung Fibroblast Vascular Endothelial Growth Factor Production Induced by Prostaglandin E₂. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 571-581.	2.9	11
148	PGE2DesensitizesÎ²-Agonist Effect on Human Lung Fibroblast-Mediated Collagen Gel Contraction through Upregulating PDE4. Mediators of Inflammation, 2013, 2013, 1-9.	3.0	1
149	Effect of budesonide on fibroblast-mediated collagen gel contraction and degradation. Journal of Inflammation Research, 2013, 6, 25.	3.5	9
150	A Randomized Placebo-Controlled Trial of Varenicline for Smoking Cessation Allowing Flexible Quit Dates. Nicotine and Tobacco Research, 2012, 14, 343-350.	2.6	79
151	Prostaglandin E₂Stimulates the Production of Vascular Endothelial Growth Factor through the E-Prostanoidâ€“2 Receptor in Cultured Human Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 217-223.	2.9	24
152	Inflammation in COPD: Implications for Management. American Journal of Medicine, 2012, 125, 1162-1170.	1.5	86
153	Preface. Medical Clinics of North America, 2012, 96, xi-xii.	2.5	0
154	Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2012, 13, 291-297.	2.5	193
155	Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1065-1072.	5.6	353
156	Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. Respiratory Research, 2012, 13, 12.	3.6	26
157	Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. PLoS ONE, 2012, 7, e37483.	2.5	633
158	Efficacy of a flexible quit date versus an a priori quit date approach to smoking cessation: A cross-study analysis. Addictive Behaviors, 2011, 36, 1288-1291.	3.0	12
159	Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine, 2011, 105, 1176-1188.	2.9	27
160	The future of chronic obstructive pulmonary disease treatmentâ€”difficulties of and barriers to drug development. Lancet, The, 2011, 378, 1027-1037.	13.7	84
161	Inflammatory cytokines regulate endothelial cell survival and tissue repair functions via NF-κB signaling. Journal of Inflammation Research, 2011, 4, 127.	3.5	17
162	Long-term Safety and Efficacy of Indacaterol, a Long-Acting Î²2-Agonist, in Subjects With COPD. Chest, 2011, 140, 68-75.	0.8	126

#	Article	IF	Citations
163	Differentiation of embryonic stem cells into fibroblast-like cells in three-dimensional type I collagen gel cultures. In Vitro Cellular and Developmental Biology - Animal, 2011, 47, 114-124.	1.5	16
164	Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respiratory Research, 2011, 12, 18.	3.6	244
165	Determinants of Depression in the ECLIPSE Chronic Obstructive Pulmonary Disease Cohort. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 604-611.	5.6	250
166	Prostaglandin E2Inhibits Human Lung Fibroblast Chemotaxis through Disparate Actions on Different E-Prostanoid Receptors. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 99-107.	2.9	25
167	Rationale and Emerging Approaches for Targeting Lung Repair and Regeneration in the Treatment of Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2011, 8, 368-375.	3.5	22
168	Effects of Varenicline on Smoking Cessation in Patients With Mild to Moderate COPD. Chest, 2011, 139, 591-599.	0.8	199
169	Republished editorial: Hypothesis: in COPD, a pound of cure may be better than an ounce of prevention. Postgraduate Medical Journal, 2011, 87, 793-794.	1.8	0
170	COPD Heterogeneity: What This Will Mean in Practice. Respiratory Care, 2011, 56, 1181-1187.	1.6	16
171	Changes in Forced Expiratory Volume in 1 Second over Time in COPD. New England Journal of Medicine, 2011, 365, 1184-1192.	27.0	811
172	Efficacy of Varenicline to Prompt Quit Attempts in Smokers Not Currently Trying to Quit: A Randomized Placebo-Controlled Trial. Nicotine and Tobacco Research, 2011, 13, 955-964.	2.6	60
173	Pharmacological Therapy: Novel Approaches. , 2011, , 129-147.		0
174	Pathogenesis of chronic obstructive pulmonary disease. Pneumonologia I Alergologia Polska, 2011, 79, 132-8.	0.6	3
175	Hepatic growth factor (HGF) inhibits cigarette smoke extract induced apoptosis in human bronchial epithelial cells. Experimental Cell Research, 2010, 316, 3501-3511.	2.6	16
176	Chronic Obstructive Pulmonary Disease Biomarker(s) for Disease Activity Neededâ€"Urgently. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 863-864.	5.6	85
177	Reduced miR-146a Increases Prostaglandin E₂ in Chronic Obstructive Pulmonary Disease Fibroblasts. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1020-1029.	5.6	176
178	Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2010, 363, 1128-1138.	27.0	2,359
179	Chronic Obstructive Pulmonary Disease Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 598-604.	5.6	898
180	Treatment of Chronic Obstructive Pulmonary Disease with Roflumilast, a New Phosphodiesterase 4 Inhibitor. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2010, 7, 141-153.	1.6	51

#	Article	IF	Citations
181	Chronic Bronchitis and Emphysema. , 2010, , 919-967.		30
182	MicroRNA-146a modulates human bronchial epithelial cell survival in response to the cytokine-induced apoptosis. Biochemical and Biophysical Research Communications, 2009, 380, 177-182.	2.1	61
183	N-acetyl-l-cysteine inhibits TGF-Î²1-induced profibrotic responses in fibroblasts. Pulmonary Pharmacology and Therapeutics, 2009, 22, 487-491.	2.6	45
184	Comorbidities, Patient Knowledge, and Disease Management in a National Sample of Patients with COPD. American Journal of Medicine, 2009, 122, 348-355.	1.5	198
185	Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease. Drugs, 2009, 69, 549-565.	10.9	171
186	Pathophysiology of COPD. , 2009, , 425-442.		2
187	Treatment for Stable COPD. , 2009, , 823-836.		1
188	Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet, The, 2009, 374, 712-719.	13.7	188
189	Budesonide and risk of pneumonia â€“ Authors' reply. Lancet, The, 2009, 374, 2051-2052.	13.7	3
190	Interview - Chronic obstructive pulmonary disease: current & future directions. Therapy: Open Access in Clinical Medicine, 2009, 6, 791-793.	0.2	1
191	Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease. Drugs, 2008, 68, 1975-2000.	10.9	176
192	NF-kappaB mediates the survival of human bronchial epithelial cells exposed to cigarette smoke extract. Respiratory Research, 2008, 9, 66.	3.6	58
193	The Efficacy and Safety of Cilomilast in COPD. Drugs, 2008, 68, 3-57.	10.9	48
194	A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine, 2008, 102, 1033-1044.	2.9	81
195	PKCÎ´ mediates thrombin-augmented fibroblast-mediated collagen gel contraction. Biochemical and Biophysical Research Communications, 2008, 369, 1199-1203.	2.1	6
196	Natural Histories of Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2008, 5, 878-883.	3.5	59
197	Foreword. Proceedings of the American Thoracic Society, 2008, 5, 795-795.	3.5	0
198	Airway Wall Thickening and Emphysema Show Independent Familial Aggregation in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 500-505.	5.6	268

#	Article	IF	Citations
199	Prostacyclin analogs stimulate VEGF production from human lung fibroblasts in culture. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L1226-L1232.	2.9	31
200	Lessons from Multidisciplinary Cross-Fertilization: Chronic Obstructive Pulmonary Disease, Lung Cancer, and Heart Disease. Proceedings of the American Thoracic Society, 2008, 5, 865-868.	3.5	2
201	Lung Fibroblast Repair Functions in Patients with Chronic Obstructive Pulmonary Disease Are Altered by Multiple Mechanisms. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 248-260.	5.6	172
202	The Many â€œSmall COPDsâ€• Chest, 2008, 134, 623-627.	0.8	102
203	Epithelial Cells and Fibroblasts. Novartis Foundation Symposium, 2008, , 104-119.	1.1	5
204	Receptor subtypes involved in lung fibroblastâ€•mediated collagen gel contraction stimulated by lysophosphatidic acid and serum. FASEB Journal, 2008, 22, 728.9.	0.5	0
205	Prostacyclin Analogs Inhibit Fibroblast Contraction of Collagen Gels through the cAMP-PKA Pathway. American Journal of Respiratory Cell and Molecular Biology, 2007, 37, 113-120.	2.9	26
206	The CC Chemokine Ligand 2 (CCL2) Mediates Fibroblast Survival through IL-6. American Journal of Respiratory Cell and Molecular Biology, 2007, 37, 121-128.	2.9	65
207	The Safety and Efficacy of Infliximab in Moderate to Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 926-934.	5.6	393
208	Cultured Lung Fibroblasts from Ovalbumin-Challenged â€œAsthmaticâ€•Mice Differ Functionally from Normal. American Journal of Respiratory Cell and Molecular Biology, 2007, 37, 424-430.	2.9	45
209	What have we learned from large drug treatment trials in COPD?. Lancet, The, 2007, 370, 774-785.	13.7	57
210	Prostaglandin E2protects human lung fibroblasts from cigarette smoke extract-induced apoptosis via EP2receptor activation. Journal of Cellular Physiology, 2007, 210, 99-110.	4.1	23
211	Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine and Tobacco Research, 2006, 8, 169-191.	2.6	77
212	COPD: the dangerous underestimate of 15%. Lancet, The, 2006, 367, 1216-1219.	13.7	220
213	Smad3 mediates TGF-Î²1-induced collagen gel contraction by human lung fibroblasts. Biochemical and Biophysical Research Communications, 2006, 339, 290-295.	2.1	58
214	Cilomilast for COPD. Chest, 2006, 129, 56-66.	0.8	105
215	Reactive Nitrogen Species Augment Fibroblast-Mediated Collagen Gel Contraction, Mediator Production, and Chemotaxis. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 592-599.	2.9	50
216	Chronic Obstructive Pulmonary Disease: Linking Outcomes and Pathobiology of Disease Modification. Proceedings of the American Thoracic Society, 2006, 3, 276-280.	3.5	34

#	Article	IF	Citations
217	Cigarette Smoke Inhibits Alveolar Repair: A Mechanism for the Development of Emphysema. Proceedings of the American Thoracic Society, 2006, 3, 703-708.	3.5	114
218	Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial. Nicotine and Tobacco Research, 2006, 8, 555-564.	2.6	67
219	Efficacy and Safety of the Novel Selective Nicotinic Acetylcholine Receptor Partial Agonist, Varenicline, for Smoking Cessation. Archives of Internal Medicine, 2006, 166, 1571.	3.8	345
220	Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine and Tobacco Research, 2006, 8, 599-622.	2.6	75
221	Varenicline, an Î±4Î²2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2006, 296, 47.	7.4	1,231
222	Pathogenesis of COPD. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 142-153.	2.1	155
223	Challenges and Opportunities for Combination Therapy in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2005, 2, 391-393.	3.5	5
224	Clinical Approach to Patients with Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. Proceedings of the American Thoracic Society, 2005, 2, 94-100.	3.5	33
225	Cigarette Smoke Extract Induces DNA Damage but Not Apoptosis in Human Bronchial Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 121-129.	2.9	98
226	Smad3 mediates TGF-Î²1 induction of VEGF production in lung fibroblasts. Biochemical and Biophysical Research Communications, 2005, 327, 393-398.	2.1	75
227	Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respiratory Medicine, 2005, 99, 1546-1554.	2.9	59
228	TGF-Î²1 and serum both stimulate contraction but differentially affect apoptosis in 3D collagen gels. Respiratory Research, 2005, 6, 141.	3.6	29
229	Minimal Clinically Important Difference, Clinical Perspective: An Opinion. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 51-55.	1.6	17
230	Exacerbations and Progression of Disease in Asthma and Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2004, 1, 88-92.	3.5	54
231	Reversible Cigarette Smoke Extractâ€“Induced DNA Damage in Human Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 483-490.	2.9	79
232	Antiinflammatory Therapies Other Than Corticosteroids. Proceedings of the American Thoracic Society, 2004, 1, 282-287.	3.5	7
233	Looking at the Patient â€" Approaching the Problem of COPD. New England Journal of Medicine, 2004, 350, 965-966.	27.0	40
234	Cigarette Smoke in Research. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 479-480.	2.9	44

#	Article	IF	Citations
235	IL-4 and IL-13 Induce Chemotaxis of Human Foreskin Fibroblasts, But Not Human Fetal Lung Fibroblasts. Inflammation, 2004, 28, 33-37.	3.8	5
236	Cells Derived from the Circulation Contribute to the Repair of Lung Injury. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1158-1163.	5.6	155
237	Cytokines modulate cilomilast response in lung fibroblasts. Clinical Immunology, 2004, 111, 297-302.	3.2	13
238	Treatment of stable chronic obstructive pulmonary disease. Lancet, The, 2004, 364, 791-802.	13.7	88
239	Glucocorticoids modulate TGF-beta production by human fetal lung fibroblasts. Inflammation, 2003, 27, 9-19.	3.8	32
240	Cigarette smoke extract inhibits chemotaxis and collagen gel contraction mediated by human bone marrow osteoprogenitor cells and osteoblast-like cells. Osteoporosis International, 2003, 14, 235-242.	3.1	33
241	Pathogenesis of COPD. Clinical Cornerstone, 2003, 5, 11-16.	0.7	7
242	Smad3 mediates the TGF-?-induced contraction of type I collagen gels by mouse embryo fibroblasts. Cytoskeleton, 2003, 54, 248-253.	4.4	38
243	TH2 Cytokine-enhanced and TGF-Î²-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-Î³ and corticosteroids. Journal of Allergy and Clinical Immunology, 2003, 111, 1307-1318.	2.9	117
244	COPD: treatments benefit patients. Lancet, The, 2003, 361, 444-445.	13.7	17
245	Targeting smokers at increased risk for relapse: treating women and those with a history of depression. Nicotine and Tobacco Research, 2003, 5, 99-109.	2.6	78
246	Antiinflammatory Effects of the Phosphodiesterase-4 Inhibitor Cilomilast (Ariflo) in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 976-982.	5.6	207
247	The Breathlessness, Cough, and Sputum Scale. Chest, 2003, 124, 2182-2191.	0.8	104
248	Effect of cigarette smoke on fibroblast-mediated gel contraction is dependent on cell density. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 284, L205-L213.	2.9	31
249	Overview of causes of COPD. Postgraduate Medicine, 2002, 111, 28-38.	2.0	12
250	PDE4 Inhibitors Attenuate Fibroblast Chemotaxis and Contraction of Native Collagen Gels. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 694-701.	2.9	85
251	PGD2Modulates Fibroblast-Mediated Native Collagen Gel Contraction. American Journal of Respiratory Cell and Molecular Biology, 2002, 27, 375-381.	2.9	19
252	Interleukin-4â€“ and Interleukin-13â€“Enhanced Transforming Growth Factor-Î² 2 Production in Cultured Human Bronchial Epithelial Cells Is Attenuated by Interferon-Î³. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 484-490.	2.9	84

#	Article	IF	Citations
253	Evaluation of subclinical respiratory tract inflammation in heavy smokers who switch to a cigarette-like nicotine delivery device that primarily heats tobacco. Nicotine and Tobacco Research, 2002, 4, 467-476.	2.6	31
254	New therapeutic drugs in the management of chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2002, 8, 106-111.	2.6	7
255	COPD in 2001. Chest, 2002, 121, 113S-115S.	0.8	15
256	Th2 cytokine regulation of type I collagen gel contraction mediated by human lung mesenchymal cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 282, L1049-L1056.	2.9	64
257	Activation of protein kinase A accelerates bovine bronchial epithelial cell migration. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 282, L1108-L1116.	2.9	44
258	Glutathione prevents inhibition of fibroblast-mediated collagen gel contraction by cigarette smoke. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 283, L409-L417.	2.9	36
259	Nerve growth factor stimulates fibronectin-induced fibroblast migration. Translational Research, 2002, 140, 329-335.	2.3	42
260	Glucocorticoids modulate TGF-beta production. Inflammation, 2002, 26, 279-290.	3.8	37
261	Prostaglandin E₂inhibits fibroblast chemotaxis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 281, L1257-L1263.	2.9	145
262	Alternative Mechanisms for Long-Acting Î²2-Adrenergic Agonists in COPD. Chest, 2001, 120, 258-270.	0.8	156
263	Glucocorticoids and TGF-beta1 synergize in augmenting fibroblast mediated contraction of collagen gels. Inflammation, 2001, 25, 109-117.	3.8	27
264	Cigarette Smoke Inhibits Human Bronchial Epithelial Cell Repair Processes. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 772-779.	2.9	145
265	Retinoic Acid Attenuates Cytokine-Driven Fibroblast Degradation of Extracellular Matrix in Three-Dimensional Culture. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 620-627.	2.9	30
266	Cytokine Inhibition of Fibroblast-Induced Gel Contraction Is Mediated by PGE₂and NO Acting Through Separate Parallel Pathways. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 245-253.	2.9	65
267	Effect of Initial Collagen Concentration on Fibroblast Mediated Contraction of Collagen Gels. Chest, 2000, 117, 234S-235S.	0.8	11
268	Chicken Soup Inhibits Neutrophil Chemotaxis In Vitro. Chest, 2000, 118, 1150-1157.	0.8	78
269	Modification of Type I Collagenous Gels by Alveolar Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2000, 22, 702-707.	2.9	21
270	Anticholinergic bronchodilators in combination. Expert Opinion on Pharmacotherapy, 2000, 1, 1281-1287.	1.8	4

#	Article	IF	Citations
271	Are higher doses of nicotine replacement more effective for smoking cessation?. Nicotine and Tobacco Research, 1999, 1, 169-174.	2.6	139
272	A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation. New England Journal of Medicine, 1999, 340, 685-691.	27.0	1,495
273	Glucocorticoids Augment Fibroblast-Mediated Contraction of Collagen Gels by Inhibition of Endogenous PGE Production. Proceedings of the Association of American Physicians, 1999, 111, 249-258.	2.0	30
274	Fibronectin production by cultured human lung fibroblasts in three-dimensional collagen gel culture. In Vitro Cellular and Developmental Biology - Animal, 1998, 34, 203-210.	1.5	31
275	Human bronchial epithelial cells modulate collagen gel contraction by fibroblasts. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1998, 274, L119-L126.	2.9	39
276	Human bronchial epithelial cells can contract type I collagen gels. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1998, 274, L58-L65.	2.9	19
277	Selective Migration of Î±-Smooth Muscle Actin-Positive Myofibroblasts toward Fibronectin in the Boyden's Blindwell Chamber. Clinical Science, 1997, 93, 355-362.	4.3	23
278	Antiproteases Attenuate the release of Neutrophil Chemotactic Activity from Bronchial Epithelial Cells Induced by Smoke. Experimental Lung Research, 1996, 22, 1-19.	1.2	4
279	Regulation of fibroblast proliferation in three-dimensional collagen gel matrix. In Vitro Cellular and Developmental Biology - Animal, 1996, 32, 427-433.	1.5	106
280	Extended Therapy With Ipratropium Is Associated With Improved Lung Function in Patients With COPD. Chest, 1996, 110, 62-70.	0.8	117
281	Cigarette Smoke Stimulates Release of Neutrophil Chemotactic Activity from Cultured Bovine Bronchial Epithelial Cells. Clinical Science, 1995, 88, 337-344.	4.3	29
282	Grain dusts and grain plant components vary in their ability to recruit neutrophils. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1995, 46, 425-441.	2.3	10
283	Induction of bovine bronchial epithelial cell filopodia by tetradecanoyl phorbol acetate, calcium ionophore, and lysophosphatidic acid. Journal of Cellular Physiology, 1995, 164, 123-131.	4.1	11
284	Viral Infection of Bovine Bronchial Epithelial Cells Induces Increased Neutrophil Chemotactic Activity and Neutrophil Adhesion. Clinical Science, 1993, 85, 753-760.	4.3	13
285	The Bronchitis Index. Chest, 1993, 103, 1482-1488.	0.8	41
286	Modulation of Fibronectin Production of Bovine Bronchial Epithelial Cells by Transforming Growth Factor-Î². American Journal of Respiratory Cell and Molecular Biology, 1992, 7, 149-155.	2.9	54
287	Morphological Study of Bovine Lung Grafted into the Hamster Cheek Pouch. Experimental Lung Research, 1992, 18, 145-154.	1.2	0
288	Pulmonary Complications of Transplantation. Annual Review of Medicine, 1992, 43, 425-435.	12.2	8

#	Article	IF	Citations
289	Transforming Growth Factor-Î² Stimulates the Expression of Desmosomal Proteins in Bronchial Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 1992, 6, 439-445.	2.9	42
290	Serum-free culture of fractionated bovine bronchial epithelial cells. In Vitro Cellular & Developmental Biology, 1992, 28, 39-46.	1.0	53
291	Induction of fibronectin gene expression by transforming growth factor beta-1 is attenuated in bronchial epithelial cells by ADP-ribosyltransferase inhibitors. Journal of Cellular Physiology, 1992, 152, 274-280.	4.1	9
292	Augmentation of Functional Prostaglandin E Levels on the Respiratory Epithelial Surface by Aerosol Administration of Prostaglandin E. The American Review of Respiratory Disease, 1991, 144, 1080-1084.	2.9	121
293	Complete Resolution of Roentgenographic Changes in a Patient with Pulmonary Histiocytosis X. Chest, 1990, 98, 765-767.	0.8	71
294	Lower respiratory tract inflammation in grain farmers. American Journal of Industrial Medicine, 1990, 17, 75-76.	2.1	18
295	Evaluation of Elastase and Antielastase Balance in Patients with Chronic Bronchitis and Pulmonary Emphysema. The American Review of Respiratory Disease, 1990, 142, 57-62.	2.9	136
296	ORGANIC DUST TOXIC SYNDROME: AN ACUTE FEBRILE REACTION TO ORGANIC DUST EXPOSURE DISTINCT FROM HYPERSENSITIVITY PNEUMONITIS. Journal of Toxicology: Clinical Toxicology, 1990, 28, 389-420.	1.5	66
297	Fractional Processing of Sequential Bronchoalveolar Lavage to Separate Bronchial and Alveolar Samples. The American Review of Respiratory Disease, 1990, 141, 208-217.	2.9	193
298	Bronchial Epithelial Cells Produce Lung Fibroblast Chemotactic Factor: Fibronectin. American Journal of Respiratory Cell and Molecular Biology, 1989, 1, 13-20.	2.9	84
299	Cytopathology of Opportunistic Infection in Bronchoalveolar Lavage. American Journal of Clinical Pathology, 1987, 88, 421-428.	0.7	23
300	Elevation of chemotactic factor inactivator in alcoholic liver disease. Hepatology, 1987, 7, 872-877.	7.3	20
301	Localization of the human fibronectin (FN) gene on chromosome 8 by a specific enzyme immunoassay. Biochemical Genetics, 1981, 19, 551-566.	1.7	26
302	Upper Airway Diseases. , 0, , 513-527.		0